Fast track designation granted to MuDelta for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d)

Furiex Pharmaceuticals announced that the FDA has granted fast track designation to MuDelta for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d). At this time, MuDelta is currently in an ongoing Phase 2 clinical trial.

MuDelta is a novel mu-opioid receptor agonist and delta-opioid receptor antagonist. The early pre-clinical and Phase 1 clinical data for MuDelta suggest this combination of opioid modulators may provide effective relief for both pain and diarrheal symptoms of IBS-d without the constipating effects typically seen with mu receptor agonists. Pharmacology data suggest that MuDelta acts locally in the digestive tract, thus having a low potential for systemic side effects.

For more information call (919) 456-7814 or visit www.furiex.com